Ridgeland Medical Clinic - Medicare Primary Care in Ridgeland, MS

Ridgeland Medical Clinic is a medicare enrolled primary clinic (Family Medicine) in Ridgeland, Mississippi. The current practice location for Ridgeland Medical Clinic is 587 Highway 51 Ste T, Ridgeland, Mississippi. For appointments, you can reach them via phone at (601) 790-7711. The mailing address for Ridgeland Medical Clinic is 587 Highway 51 Ste T, Ridgeland, Mississippi and phone number is (601) 790-7711.

Ridgeland Medical Clinic is licensed to practice in * (Not Available) (license number ). The clinic also participates in the medicare program and its NPI number is 1053917849. This medical practice accepts medicare insurance (which means this clinic accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance). However, please confirm if they accept your insurance at (601) 790-7711.

Contact Information

Ridgeland Medical Clinic
587 Highway 51 Ste T
Ridgeland
MS 39157-2567
(601) 790-7711
(601) 790-7712

Primary Care Clinic Profile

Full NameRidgeland Medical Clinic
SpecialityFamily Medicine
Location587 Highway 51 Ste T, Ridgeland, Mississippi
Authorized Official Name and PositionJody Adams (NURSE PRACTITIONER)
Authorized Official Contact6017907711
Accepts Medicare InsuranceYes. This clinic participates in medicare program and accept medicare insurance.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Ridgeland Medical Clinic
587 Highway 51 Ste T
Ridgeland
MS 39157-2567

Ph: (601) 790-7711
Ridgeland Medical Clinic
587 Highway 51 Ste T
Ridgeland
MS 39157-2567

Ph: (601) 790-7711

NPI Details:

NPI Number1053917849
Provider Enumeration Date12/08/2020
Last Update Date12/08/2020

Medicare PECOS Information:

Medicare PECOS PAC ID9032524400
Medicare Enrollment IDO20210217000175

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Medical Identifiers

Medical identifiers for Ridgeland Medical Clinic such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1053917849NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207Q00000XFamily Medicine (* (Not Available))Primary

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Ridgeland Medical Clinic acts as a billing entity for following providers:
Provider NameBarbara A Bradley
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1124064068
PECOS PAC ID: 1951203181
Enrollment ID: I20040127000212

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameMassie Headley
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1649249426
PECOS PAC ID: 0446145288
Enrollment ID: I20040219000497

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameJody T Adams
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1780652362
PECOS PAC ID: 1456246131
Enrollment ID: I20040220000479

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameLaurie B Robinson
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1053355024
PECOS PAC ID: 7911976352
Enrollment ID: I20041001000163

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameWilliam D. Whitton
Provider TypePractitioner - Family Practice
Provider IdentifiersNPI Number: 1790754307
PECOS PAC ID: 8325027063
Enrollment ID: I20041110000268

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameCalvin Ramsey
Provider TypePractitioner - Internal Medicine
Provider IdentifiersNPI Number: 1508919648
PECOS PAC ID: 0143131037
Enrollment ID: I20111108000829

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameAmanda B Greene
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1083040562
PECOS PAC ID: 0547277980
Enrollment ID: I20140617002012

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameLeah S Mcgehee
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1265825962
PECOS PAC ID: 5193044931
Enrollment ID: I20150429001873

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameSabrina B Matthews
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1043662430
PECOS PAC ID: 7416953047
Enrollment ID: I20160913000669

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameLonnie L Moore
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1962852988
PECOS PAC ID: 8820386451
Enrollment ID: I20161013001187

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameJason Brian Copeland
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1326538315
PECOS PAC ID: 6901157874
Enrollment ID: I20180918000176

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

Provider NameMary Hannah Bucklew
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1467024901
PECOS PAC ID: 0446657340
Enrollment ID: I20210920002337

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more Medical News

› Verified 7 days ago

News Archive

Premier's ClinicalAdvisor offers customized benchmarking and regulatory reporting solution for hospitals and health systems

To help hospitals achieve maximum revenue retention as a part of Medicare's Recovery Audit Contractor (RAC) program, the Premier healthcare alliance has enhanced its quality benchmarking and regulatory reporting solution to include RAC capabilities.

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

New conservation practice could reduce nitrogen from agricultural drainage, study shows

Every summer, a "dead zone" forms in the Gulf of Mexico. Plumes of oxygen-robbing algae, fed by excess nitrogen coming in from the Mississippi River, kill off marine life and threaten the livelihoods of those who fish the Gulf. States bordering the Mississippi River are putting strategies in place to limit nitrogen from wastewater treatment plants, surface runoff, and agricultural fields.

Read more News

› Verified 7 days ago


Family Medicine in Ridgeland, MS

Pmb Family Medical, Llc
Primary Care Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 710 Highland Colony Pkwy Ste A-1, Ridgeland, MS 39157
Phone: 601-398-9886    
Fitvisits Llc
Primary Care Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 731 S Pear Orchard Rd Ste 16, Ridgeland, MS 39157
Phone: 662-213-6555    
Natural Health Project Llc
Primary Care Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 555 Highway 51, Ridgeland, MS 39157
Phone: 601-856-2383    Fax: 601-856-3955
Advance Medical House Calls & Family Clinic
Primary Care Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 299 Highway 51 Ste F1, Ridgeland, MS 39157
Phone: 601-397-4079    Fax: 601-398-2149
Integrated Medical And Wellness Clinic Of Mississippi Llc
Primary Care Clinic
Medicare: Medicare Enrolled
Practice Location: 212 Draperton Ct, Ridgeland, MS 39157
Phone: 769-300-9040    Fax: 769-300-9055
Magnolia Premier Medical Group Pllc
Primary Care Clinic
Medicare: Medicare Enrolled
Practice Location: 1000 Highland Colony Pkwy Ste 35203, Ridgeland, MS 39157
Phone: 601-613-5682    Fax: 601-372-3059

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.